Splash Beverage Group 携手 Lupvindol,推进 Cannepil 动物药研发与FDA申报

美股速递
Aug 05

根据美国证券交易委员会(SEC)最新披露的文件,Splash Beverage Group Inc. 在动物药开发领域迈出关键一步。公司宣布,已指定 Lupvindol 主导从 Cannepil 提取的动物药研发工作,并全面负责其与 FDA(美国食品药品监督管理局)相关的监管申报事宜。这一举措,标志着该公司在拓展非人用药品业务上,战略布局正逐步深入。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10